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Abstract:Metal–organic frameworks (MOFs) are emerging as
leading candidates for nanoscale drug delivery, as a conse-
quence of their high drug capacities, ease of functionality, and
the ability to carefully engineer key physical properties. Despite
many anticancer treatment regimens consisting of a cocktail of
different drugs, examples of delivery of multiple drugs from
one MOF are rare, potentially hampered by difficulties in
postsynthetic loading of more than one cargo molecule.
Herein, we report a new strategy, multivariate modulation,
which allows incorporation of up to three drugs in the Zr MOF
UiO-66 by defect-loading. The drugs are added to one-pot
solvothermal synthesis and are distributed throughout the
MOF at defect sites by coordination to the metal clusters. This
tight binding comes with retention of crystallinity and porosity,
allowing a fourth drug to be postsynthetically loaded into the
MOFs to yield nanoparticles loaded with cocktails of drugs
that show enhancements in selective anticancer cytotoxicity
against MCF-7 breast cancer cells in vitro. We believe that
multivariate modulation is a significant advance in the
application of MOFs in biomedicine, and anticipate the
protocol will also be adopted in other areas of MOF chemistry,
to easily produce defective MOFs with arrays of highly
functionalised pores for potential application in gas separa-
tions and catalysis.
Introduction
Metal–organic frameworks (MOFs)[1] are a new genera-
tion of highly porous macromolecular structures composed of
metal ions or clusters linked by multidentate organic bridging
ligands, which, owing to their attractive properties, have
notable potential for applications in different contexts,
including gas capture, storage and separation,[2] catalysis,[3]
water treatment[4] and drug delivery.[5] MOFs have almost
infinite tunability due to the effectively unlimited range of
metal ions and ligands available to form their structures.[6]
Additionally, a class of mixed-linker materials—so-called
multivariate (MTV) MOFs—have been synthesised, tuning
physicochemical properties and their performance in differ-
ent applications. By introducing multiple analogous linkers
into one framework and effectively forming a solid solution of
organic functionality within the pores (Figure 1a), coopera-
tive effects for gas adsorption and heterogeneous catalysis
have been found,[7] for example, Yaghi et al. synthesised
MTV-MOF-5 type structures that contain up to eight distinct
functionalities (by introducing eight functionalised tereph-
thalate linkers during synthesis) in one phase, resulting, in the
case of a MOF linked by three different terephthalate
derivatives, in up to 400% better CO2 selectivity (vs. CO)
than their separate MOF-5 counterparts.[7c]
MOFs have been proposed as an attractive alternative to
mitigate drawbacks that other drug delivery systems (DDSs)
face,[5, 8] as they can exhibit low toxicity, good clearance, high
drug loadings, and are easy to functionalise, yet examples of
MTV-MOFs for drug delivery applications are still limited.[9]
The coordination modulation (CM) protocol[10]—in which
monotopic ligands (modulators) compete with the MOF
linkers for metal cluster coordination sites during synthesis—
has been widely studied to control physical properties such as
size,[11] crystallinity, colloidal dispersion,[12] stability and
porosity (through defect chemistry),[13]while we have recently
shown that it can be used to control MOF surface chemistry
and functionality.[14] Additionally, we have introduced the
Figure 1. Concepts for synthesis of UiO-66 as a) a multivariate, or
MTV MOF with multiple mixed linkers, or b) using multivariate
modulation, which we have termed MTVM, to install multiple different
modulators as defects within one MOF.
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concept of in situ defect drug loading in MOFs, showing that
using dichloroacetic acid as a modulator during assembly of
UiO-66-type MOFs of ideal formula [Zr6O4(OH)4(L)6]n,
results in highly porous, well-dispersed nanoparticles with
a high incorporation of dichloroacetate (DCA) as a defect-
compensating ligand.[15] The protocol is amenable to surface
functionalisation, both during synthesis by incorporating
a second modulator and through postsynthetic coating, and
also allows further postsynthetic drug loading of 5-fluorour-
acil (5-FU) into the MOF pores,[14c] in both cases without
major DCA leakage. Many clinical anticancer treatments
involve a cocktail of drugs (e.g. FOLFORINOX combines 5-
FU, leucovorin, irinotecan and oxaliplatin against metastatic
pancreatic adenocarcinoma)[16] yet examples of MOFs capa-
ble of delivering multiple drugs are relatively scarce,[8d,17]
suggesting defect-loading could be an attractive strategy for
preparing multimodal chemotherapeutic formulations.
Despite the fact that multiple drugs contain metal-binding
units such as carboxylates, and the easier industrial manufac-
turing of producing drug-loaded MOFs in one-pot syntheses,
examples of drugs used as modulators are still uncommon in
the literature.[18] Based on our previous work[14c,15] we sought
to examine the potential for incorporating multiple drugs as
modulators in one-pot syntheses in a process we call MTV
modulation (MTVM, Figure 1b). Herein we show it is
possible to introduce up to three drugs into the Zr benzene-
1,4-dicarboxylate (BDC) MOF UiO-66 with versatility based
on the simultaneous introduction of carboxylate and phos-
phonate-containing moieties. Our MTVM protocol provides
particle size control (ca. 100 nm), while the resultant multi-
drug MTVM MOFs retain their porosity, which is used to
postsynthetically store a fourth drug (Scheme 1 and SI,
Section S2). We believe that the MTVM protocols could be
applied to a wide range of modulators for alternative
enhanced applications such as catalysis and gas adsorption/
separation.
Results and Discussion
Previously, we and others have shown that UiO-66 is
biocompatible,[8c,19] while the cytotoxicity of DCA-loaded
MOFs is dependent on surface chemistry,[14c,d] and incorpo-
ration of a second drug can dramatically enhance overall
cytotoxicity.[15] As well as DCA, we have chosen a-cyano-4-
hydroxycinnamic acid (a-CHC), a molecule recently pro-
posed as an anticancer agent, due to the relatively low pKa of
its carboxylate unit (2.2), comparable with the one of DCA
(1.4). As a proof-of-concept of the effect of the pKa in the
drug-modulated synthesis, we have also studied modulation
with ibuprofen (IBU), due to its similar structure to a-CHC
and the higher pKa of its carboxylate (4.9). Alendronate
(AL)[20] is an anticancer drug which contains two phospho-
nates—which are expected to show higher affinity for Zr than
carboxylates—with a first pKa of 2.4. 5-FU has been chosen as
a drug to be loaded postsynthetically, as it does not contain
a metal-binding unit.
At first, we postsynthetically loaded our previously
reported DCA@UiO-66,[15] prepared by coordination modu-
lation, separately with 5-FU, a-CHC, IBU, and AL
(Scheme 1). While 5-FU loading resulted in ca. 1.2% (w/w)
incorporation with minimal DCA leakage, as determined by
ICP-OES, postsynthetic loading of drugs containing metal-
binding units resulted in partial or total displacement ofDCA
(Table S1), as determined by 1H NMR spectroscopic analysis
of acid-digested samples, suggesting their loading occurs
through attachment to the Zr positions (subsequently detach-
ing DCA) rather than pore storage (see SI, Section S3.1 for
full characterisation). AL loading resulted in a complete
structural change, likely due to the affinity of its phosphonate
groups for Zr inducing breakdown,[21] again confirming the
competing coordination of the drugs. As such, this postsyn-
thetic process was not considered viable for multiple drug
loading.
Modulation with a single drug, either a-CHC, IBU orAL,
results in crystalline MOFs with the UiO topology,[22] as
confirmed by PXRD (see SI, Section S3.2 for full character-
isation), although in the case of AL@UiO-66, new Bragg
peaks could be observed in the PXRD pattern, suggesting
some incorporation of the bis-phosphonateAL as a linker and
subsequent minor structural alteration. 1H NMR spectra of
the acid digested samples confirmed the presence of modu-
lators, and their content is tabulated in Table S2. However,
scanning electron microscopy (SEM) showed that all the
individual drug-modulated MOFs consisted of aggregates of
various sizes and shapes, and hence could not be used for
biomedical application, as monodisperse colloidally stable
samples are imperative for drug delivery.[23]
AddingDCA as a co-modulator of each MTVM synthesis
overcomes the sample aggregation issue, resulting in crystal-
line MOFs with Bragg reflection peaks characteristic of the
UiO-66 topology in all cases (Figure 2a), although AL/
DCA@UiO-66 had poorer crystallinity with some additional
reflections again suggestive of structural change. The modu-
lator content (see SI, Table S3) can be measured in mol%
compared to the linker BDC by 1H NMR spectroscopic
digestion; while this allows an assessment of relative incor-
Scheme 1. Syntheses of drug modulated MOFs and their postsynthetic
drug loading. The chemical structures (coordinating groups in red)
and abbreviations of the drugs are shown in the inset.
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poration of drugs (and thus defectivity) it cannot yield weight
percentage loading due to the complexity of defect formation.
Molar loading values are in concordance with the modulatorsQ
expected affinities for Zr. a-CHC/DCA@UiO-66 contained
6.7 mol% of a-CHC (ca. 1 a-CHC per 12 BDC), and
& 35 mol% of DCA (ca. 1 DCA per 3 BDC) whilst IBU/
DCA@UiO-66 showed a smaller degree of incorporation of
IBU (2.9 mol% compared to BDC) due to its higher pKa,
[13a]
and similarly & 37 mol% of DCA. Alendronate had the
highest incorporation, again likely representative of its
ditopicity and the Zr-phosphonate affinity,[21] as AL/
DCA@UiO-66 contained 38.1 mol% (ca. 1 AL per 2.5
BDC), suggesting its possible role as a linker, and
18.8 mol% of DCA (ca. 1 DCA per 3.5 BDC). Thermogravi-
metric analysis of samples showed complex overlapping
thermal degradation processes, often with lowered thermal
stabilities compared to pristine UiO-66, confirming that the
drugs are anchored to the MOF structures but not allowing
quantification of drug loading using this technique.
The samples were highly porous (Figure 2b), confirming,
together with TGA and FT-IR spectroscopy (See S3.3 for full
characterisation) the attachment of the modulators to the Zr
positions. In fact, as a general trend for the DCA-modulated
IBU and a-CHC samples, porosity was notably enhanced
(SBET increased from & 1000–1100 m2g@1 to & 1500 m2g@1)
compared to the single-drug modulated analogues, whereas in
the case of AL/DCA@UiO-66 the porosity of the sample is
reduced (SBET decreased from 1245 m
2g@1 to 369 m2g@1) upon
DCA addition, likely as a consequence of the much higher
incorporation of alendronate and poorer overall crystallinity
indicated by PXRD. Unfortunately, due to the defective
nature of the samples, in which modulators replace the linkers
in the structure, exact structural determination is trouble-
some. TheMOFs were easily dispersed in phosphate-buffered
saline (PBS 10X, pH 7.4), with dynamic light scattering (DLS)
measurements (Figure 2c) in great agreement with the
particle size determined by SEM (ca. 100 nm, Figure 2d),
confirming, together with our previous results,[14c,15] thatDCA
co-modulation serves as a size control protocol, that also
enhances the colloidal dispersion of the samples.[12]
This versatile synthetic protocol to introduce drugs during
synthesis using DCA as a co-modulator was further explored
to introduce three drugs (a-CHC,AL andDCA ; IBUwas not
further investigated as it is not an anticancer drug) during
synthesis into a single MTVMMOF structure to give a-CHC/
AL/DCA@UiO-66. As the Cl (DCA) and P (AL) content of
the samples can be determined by ICP-OES, and the a-CHC
content by UV/Vis spectroscopy of digested samples, the
corresponding drug loadings bymass are tabulated in Table 1,
as these values are more relevant for subsequent cytotoxicity
experiments.
Despite the significant incorporation of the multiple drugs
into UiO-66 structure (Table 1), a-CHC/AL/DCA@UiO-66
Figure 2. Characterisation of the dual and triple drug-loaded MTVM UiO-66 samples. a) Stacked partial PXRD patterns compared to that predicted
for UiO-66, confirming formation of the UiO-66 topology. b) N2 uptake isotherms (77 K, filled symbols adsorption, empty symbols desorption)
confirming retention of porosity to varying degrees. c) Dynamic light scattering (0.1 mgmL@1 in PBS 10X, pH 7.4) showing minimal aggregation.
d) SEM images confirming formation of approximately spherical nanoparticles around 100–150 nm in diameter. All scale bars are 200 nm.
Table 1: Drug loadings by mass of the MTVM MOFs examined for
cytoxicity.
MOF Drug loading [%] (w/w)
DCA[a] a-CHC[b] AL[c] 5-FU[d]
a-CHC/DCA@UiO-66 11.0% 2.0% – –
AL/DCA@UiO-66 3.7% – 27.5% –
5-FU@DCA@UiO-66 8.0% – – 1.2%
a-CHC/AL/DCA@UiO-66 3.2% 2.0% 21.6% –
5-FU@a-CHC/AL/DCA@UiO-66 3.1% 1.6% 21.3% 1.6%
[a] Determined by ICP-OES (Cl content). [b] Determined by UV/Vis
titration. [c] Determined by ICP-OES (P content). [d] Determined by ICP-
OES (F content).
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was found to be highly crystalline (Figure 2a, see SI,
Section S3.4 for full characterisation). The sample again
maintained a high AL loading of 21.6% (w/w), as well as
3.2% (w/w) loading of DCA, and 2.0% (w/w) loading of a-
CHC. Assuming binding of monoanions at defects, this
corresponds to a a-CHC :DCA:AL molecular ratio of
1:2.3:8.1, in great agreement with reports showing the high
affinity ofAL for UiO-66 Zr clusters[20] and of the role of pKa
in defect binding. TGA, FT-IR spectroscopy and N2 adsorp-
tion and desorption measurements confirmed the drugs to be
attached to the Zr positions, as a-CHC/AL/DCA@UiO-66
has a surface area of 634 m2g@1 despite containing over 25%
(w/w) of drugs in its structure (Figure 2b). The lower porosity
could also be attributed to the high incorporation of AL, as
seen with the analogous AL/DCA@UiO-66 sample. A
comparison of the drug incorporation ratios with the surface
areas and pore volumes, indicative of the level of defectivity
and/or structural change, is given in the Supporting Informa-
tion, Table S5.
Once again, size control was achieved resulting in nano-
particles of ca. 125–150 nm (Figure 2d) and the material was
well-dispersed in PBS (Figure 2c). The porosity was further
used to postsynthetically load 5-FU, resulting in a DDS, 5-
FU@a-CHC/AL/DCA@UiO-66, containing a cocktail of four
anticancer drugs. ICP-OES determined 1.6% (w/w) 5-FU
content with negligible leakage of the modulator drugs.
The MTVM drug-loaded MOFs were tested for anti-
cancer selectivity against MCF-7 breast cancer and HEK293
kidney cells by the MTS assay (See SI, Section S4) after
72 hours of incubation and compared to the effect of the free
drugs, which allows comparison with our previous work.[14c]
The similar size of all MOFs (ca. 90–150 nm) allows compar-
ison of therapeutic efficacy without concerns over major
particle size influence. For both cell lines, there is approx-
imately an order of magnitude difference in the cytotoxicities
of the free drugs, with IC50 values in the order AL < 5-FU <
a-CHC < DCA (Table S6), and each drug shows a small
selectivity for cytotoxicity towards the MCF-7 cancer cell line
compared to HEK293. In order to delineate the effects of the
MOF delivery vehicle on the efficacies of the different drugs
individually and in tandem, cytotoxicities of the MOFs
containing either AL, 5-FU or a-CHC alongside DCA are
first assessed (Figure 3).
In great agreement with our previous studies of ultra-
small UiO MOFs for dual delivery of 5-FU and DCA,[15] 5-
FU@DCA@UiO-66 was profoundly more cytotoxic than free
5-FU towards MCF-7 cells (Figure 3a), with an IC50 dose
normalised to 5-FU over 35 times lower than the free drug,
decreasing cell proliferation to values to ca. 45% after
treatment with 25 mgmL@1 of MOF for 72 hours (IC50 values
for free drugs are listed in Table S6, and are tabulated for all
MOF samples, normalised to the varying components, in
Figure 3. MTS proliferation assays of the dual-loaded MOFs towards MCF-7 cancer cells and HEK293 kidney cells compared to the free drug.
Values are normalised to the maximum possible dose of the most cytotoxic drug. a) Comparison of MCF-7 cytotoxicity of 5-FU@DCA@UiO-66
with free 5-FU. b) Comparison of cytotoxicity of 5-FU@DCA@UiO-66 towards MCF-7 vs. HEK293. c) Comparison of MCF-7 cytotoxicity of a-CHC/
DCA@UiO-66 with free a-CHC. d) Comparison of cytotoxicity of a-CHC/DCA@UiO-66 towards MCF-7 vs. HEK293. e) Comparison of MCF-7
cytotoxicity of AL/DCA@UiO-66 with free AL. f) Comparison of cytotoxicity of AL/DCA@UiO-66 towards MCF-7 vs. HEK293. Error bars represent
the standard deviation of the mean value of three independent assays.
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Tables S7 and S8). Its cytotoxic effect towards HEK293 was
ca. 21 times that of the free drug, so whilst toxicity also
increased towards non-cancerous cells, the overall selectivity
compared to the free drug improved nearly two-fold (Fig-
ure 3b). It has previously been reported that DCA enhances
the anticancer activity and selectivity of certain drugs,
including 5-FU,[24] however, doses at least ten times higher
than those used here are usually needed to generate
a synergistic effect when the drugs are not loaded into
a DDS.[15]
A pronounced enhancement of the therapeutic effect of
a-CHC towards MCF-7 cancer cells was found for a-CHC/
DCA@UiO-66 (Figure 3c). Despite both a-CHC and DCA
having IC50 doses against MCF-7 cells in the millimolar range,
the IC50 of the drug-loadedMOF towards MCF-7 corresponds
to a maximum delivered dose of a-CHC that is 27 times lower
than that for the free drug and to a delivered dose ofDCA 111
times lower than the IC50 of the free drug. This dramatic
enhancement is not observed for the HEK293 cells, where the
MOF is biocompatible up to 1 mgmL@1 of MOF (Figure 3d).
Taken together, this again corresponds to an increase in
cytotoxicity and selectivity towards MCF-7 versus HEK293.
In contrast, a decrease in the therapeutic effect of
alendronate towards MCF-7 breast cancer cells was found
forAL/DCA@UiO-66 (Figure 3e). The increase of the IC50 of
AL upon delivery from AL/DCA@UiO-66 corresponds to
a maximum delivered concentration 7 times higher than that
of the free drug. The bis-phosphonate structure ofAL is likely
to be strongly adhered to the Zr positions of the MOF, and so
incomplete release may attenuate cytotoxicity and raise the
possibility of slower, controlled release to mitigate side effects
in vivo. It is important to note that the MOF was not cytotoxic
towards HEK293 cells up to 1 mgmL@1 of MOF (Figure 3 f),
a formulation loaded with anAL content 49 times higher than
the IC50 of the free drug, meaning that although there is no
enhancement in the therapeutic activity of the drug towards
MCF-7 cancer cells, there is again a remarkable increase in its
selectivity.
For the triple-drug formulations, a-CHC/AL/DCA@UiO-
66 again increased the IC50 against MCF-7 cells when
normalised to AL content, to a dose around 1.5 times higher
than that for the free drug (Figure 4). Incubation with
25 mgmL@1 of a-CHC/AL/DCA@UiO-66 decreased MCF-7
cell proliferation to 34: 6%, further decreasing to 18: 11%
upon treatment with a concentration of 250 mgmL@1 of MOF.
Evaluating the MOFs by the loading of their most cytotoxic
drug component, AL, suggests a-CHC/AL/DCA@UiO-66
exhibits around 57 times the cytotoxicity towards MCF-7
compared to AL/DCA@UiO-66, and is also significantly
more cytotoxic than comparable doses of a-CHC/
DCA@UiO-66.
The effect towards HEK293 cells, however was remark-
ably different. a-CHC/AL/DCA@UiO-66 was found to be
biocompatible up to 1 mgmL@1 of MOF (maximum AL
delivered dose 38 times higher than the IC50 of the free drug);
the selectivity of cytotoxicity against MCF-7 versus HEK293
is again enhanced compared to AL alone.
Loading the MTVM MOF with a fourth drug, 5-FU,
resulted in a further enhancement of the IC50 dose of 5-
FU@a-CHC/AL/DCA@UiO-66 towards MCF-7 cells, with
the IC50 normalised to AL content just 10% higher than the
free drug. Biocompatibility with HEK293 cells was main-
tained up to 0.2 mgmL@1 MOF incubation MOF (maximum
AL delivered dose 7.5 times higher than the IC50 of the free
drug), suggesting that multimodal drug delivery can synerg-
istically enhance anticancer activity while conserving the
biocompatibility towards HEK293 cells at the concentrations
studied.
Conclusion
On the whole, we have demonstrated that different drugs,
containing either carboxylates or phosphonates as metal-
binding units, can be introduced to the synthesis of UiO-66—
and potentially any other Zr MOF of the UiO family—as
simultaneous modulators. The drugs become attached to the
Zr clusters of the resulting MOF, which has been found to be
related to both the pKa of the metal binding unit (the lower
the pKa, the higher the incorporation) and its chemical
functionality (phosphonates have a higher affinity for Zr than
carboxylates and are incorporated more). As the drug-
modulators are attached as defects rather than pore-loaded,
the resultant MTVM MOFs are highly porous, and we have
used their porosity to postsynthetically load 5-FU, ultimately
resulting in four drugs incorporated in significant quantities
into a single nanovector. We have shown that adding DCA to
the drug modulated syntheses also offers size control,
resulting in nanoparticles of ca. 100 nm that are well-
dispersed in PBS (10X), which enables the comparison of
Figure 4. Comparison of IC50 values, normalised to AL, for various
formulations against HEK293 and MCF-7 cells. Measurements marked
with an asterix (*) represent the maximum concentration assessed
where cell proliferation remained >90% and so IC50 values (and error
bars) cannot be calculated. In all formulations, selectivity of anticancer
cytotoxicity is enhanced when AL is incorporated in UiO-66.
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their cytotoxicity without concerns over size effects. The
anticancer therapeutic activity of the double drug combina-
tions towards MCF-7 breast cancer cells is highly increased
for 5-FU@DCA@UiO-66 and a-CHC/DCA@UiO-66 com-
pared to the free drugs, whereas the MOFs are biocompatible
to HEK293 kidney cells even at high doses, enhancing
selectivity. Although the therapeutic activity of AL when
loaded into the MOFs is reduced in all cases compared to the
free drug, likely as it is not fully released from the core of the
MOF, increases in cytotoxicity towards MCF-7 cells are noted
for treble and quadruple drug formulations as the drug
cocktails become more complex. Additionally, a drastic
increase in selectivity towards cancer cells is achieved across
the formulations; 5-FU@a-CHC/AL/DCA@UiO-66 main-
tains the cytotoxicity of free AL towards MCF-7 cells yet is
considerably more biocompatible towards HEK293 cells than
free AL, suggesting that drug delivery using MOFs as DDSs
could overcome the unwanted cytotoxic issues of some drugs.
Our MTVM protocols are highly versatile and reprodu-
cible (both carboxylates and phosphonates can be introduced
simultaneously into one single phase during synthesis), and
could be applied to almost any drug containing potential
metal-binding units (e.g. doxorobucin or paclitaxel) and to
other MOF systems, opening a broad range of possibilities
and combinations to design novel drug loaded MOFs. While
we have used biologically relevant molecules as modulators in
this study, we are convinced that the MTVM protocol can be
used to introduce modulators to enhance other applications
through cooperative effects, such as preferential gas capture
or heterogeneous catalysis, and also to tune the host-guest
interactions of the frameworks through pore environment
control to favour the uptake of certain gases (gas uptake/
separation), chelating units (water treatment/ pollutant
removal) and cooperative units for catalysis, among many
other possibilities.
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